^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersBIOMARKER:
SH2B3 mutation
i
Other names: SH2B3, SH2B Adaptor Protein 3, Lymphocyte-Specific Adapter Protein Lnk, Signal Transduction Protein Lnk, SH2B Adapter Protein 3, LNK, Lymphocyte Adapter Protein, Lymphocyte Adaptor Protein, IDDM20
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
10d
Long-term Follow-up of Gastrointestinal CAR T-cell Lymphoma: Homing, Clonal Expansion, and Response to Cyclosporine. (PubMed, Blood)
We found clinical, histological, and molecular evidence demonstrating the efficacy of cyclosporine in reducing the expanded malignant clone and achieving durable clinical remission for more than a year. Our findings highlight the complex interplay between CAR T-cell therapy, pre-existing genetic vulnerabilities, and the GI microenvironment, emphasizing the need for vigilant monitoring and tailored therapeutic strategies to address the risks associated with CAR-T lymphomagenesis.
Journal • IO biomarker
|
SH2B3 (SH2B Adaptor Protein 3) • TFCP2 (Transcription Factor CP2)
|
SH2B3 mutation
|
cyclosporine
6ms
FT400-004: Evaluate the Safety, Efficacy and Pharmacokinetics of ThisCART19A in Patients With R/R B-ALL (clinicaltrials.gov)
P1, N=16, Recruiting, Zhejiang University | Trial completion date: Apr 2024 --> Jun 2025 | Trial primary completion date: Mar 2024 --> Jun 2025
Trial completion date • Trial primary completion date
|
ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase) • PDGFRA (Platelet Derived Growth Factor Receptor Alpha) • FGFR (Fibroblast Growth Factor Receptor) • JAK2 (Janus kinase 2) • PDGFRB (Platelet Derived Growth Factor Receptor Beta) • IKZF1 (IKAROS Family Zinc Finger 1) • JAK1 (Janus Kinase 1) • IL7R (Interleukin 7 Receptor) • TCF3 (Transcription Factor 3) • SH2B3 (SH2B Adaptor Protein 3)
|
SH2B3 mutation
Share via
